NeuroMetrix (NASDAQ:NURO) Share Price Passes Above Two Hundred Day Moving Average – What’s Next?

NeuroMetrix, Inc. (NASDAQ:NURO) shares crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $4.11 and traded as high as $4.39. NeuroMetrix shares last traded at $4.42, with a volume of 1,085 shares.

Analyst Upgrades and Downgrades

Separately, StockNews.com began coverage on shares of NeuroMetrix in a research note on Wednesday, March 12th. They set a “sell” rating for the company.

NeuroMetrix Price Performance

The stock has a market cap of $9.08 million, a P/E ratio of -0.96 and a beta of 2.15. The business’s 50 day simple moving average is $4.28 and its 200 day simple moving average is $4.11.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in NeuroMetrix stock. Renaissance Technologies LLC bought a new stake in NeuroMetrix, Inc. (NASDAQ:NURO) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 11,560 shares of the medical device company’s stock, valued at approximately $46,000. Renaissance Technologies LLC owned about 0.57% of NeuroMetrix at the end of the most recent quarter. 19.40% of the stock is currently owned by institutional investors.

NeuroMetrix Company Profile

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.